Canagliflozin, a new sodium-glucose co-transport protein 2 (SGLT2) inhibitor, reduces CVD and mortality in patients with type 2 diabetes presumably via the activation of ROS/Nrf2/HO-1 path way in VSMCs [162]. This evidence concerns the gene NFE2L2 and type 2 diabetes mellitus.